Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688492 | 0.87 | POLB (1.00) | POLBMAPTSMN1; SMN2P2RX7HTT | |
| SCHEMBL15082390 | 0.81 | POLB (0.48) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL1360703 | 0.81 | POLB (0.62) | POLBP2RX7L3MBTL1KMT2AALDH1A1 | |
| Triethylene Glycol SCHEMBL1362131 | 0.79 | BRD4 (0.51) | POLBMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL15082379 | 0.77 | POLB (0.79) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL15082391 | 0.77 | POLB (0.55) | POLBMAPTSMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL3829535 | 0.77 | POLB (0.67) | POLBMAPTSMN1; SMN2P2RX7HTT | |
| SCHEMBL12145251 | 0.76 | POLB (0.68) | POLBMAPTP2RX7L3MBTL1KMT2A | |
| SCHEMBL10039387 | 0.75 | POLB (0.76) | POLBMAPTSMN1; SMN2P2RX7L3MBTL1 | |
| SCHEMBL3828937 | 0.75 | POLB (0.54) | POLBSMN1; SMN2P2RX7L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067651-B2 | 1-alkyl-5-oxopyrrolidine-3-carboxylic esters with improved biodegradability | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-11-29 | — | — | US | disclosed |
| US-20090043146-A1 | 1-Alkyl-5-oxopyrrolidine-3-carboxylic esters with improved biodegradability | CLARIANT INTERNATIONAL LTD. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043146-A1 | 1-Alkyl-5-oxopyrrolidine-3-carboxylic esters with improved biodegradability | OXER1, CYP1A1, CHRM1 | POLB 952/4885MAPT 3773/4885SMN1; SMN2 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.